Influenza virus neuraminidase (NA): a target for antivirals and vaccines

被引:44
作者
Jagadesh, Anitha [1 ]
Salam, Abdul Ajees Abdul [2 ]
Mudgal, Piya Paul [1 ]
Arunkumar, Govindakarnavar [1 ]
机构
[1] Manipal Univ, Manipal Ctr Virus Res, Reg Reference Lab Influenza Virus, ICMR Grade Virus Diagnost Lab 1, Manipal 576104, Karnataka, India
[2] Manipal Univ, Manipal Inst Technol, Dept Atom & Mol Phys, Manipal 576104, Karnataka, India
关键词
A VIRUS; SIMULTANEOUS QUANTIFICATION; STRUCTURAL-CHARACTERIZATION; VIRAL NEURAMINIDASE; ENHANCED PROTECTION; T-CELLS; HEMAGGLUTININ; ANTIBODY; INFECTION; IMMUNITY;
D O I
10.1007/s00705-016-2907-7
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Influenza, the most common infectious disease, poses a great threat to human health because of its highly contagious nature and fast transmissibility, often leading to high morbidity and mortality. Effective vaccination strategies may aid in the prevention and control of recurring epidemics and pandemics associated with this infectious disease. However, antigenic shifts and drifts are major concerns with influenza virus, requiring effective global monitoring and updating of vaccines. Current vaccines are standardized primarily based on the amount of hemagglutinin, a major surface antigen, which chiefly constitutes these preparations along with the varying amounts of neuraminidase (NA). Anti-influenza drugs targeting the active site of NA have been in use for more than a decade now. However, NA has not been approved as an effective antigenic component of the influenza vaccine because of standardization issues. Although some studies have suggested that NA antibodies are able to reduce the severity of the disease and induce a long-term and cross-protective immunity, a few major scientific issues need to be addressed prior to launching NA-based vaccines. Interestingly, an increasing number of studies have shown NA to be a promising target for future influenza vaccines. This review is an attempt to consolidate studies that reflect the strength of NA as a suitable vaccine target. The studies discussed in this article highlight NA as a potential influenza vaccine candidate and support taking the process of developing NA vaccines to the next stage.
引用
收藏
页码:2087 / 2094
页数:8
相关论文
共 61 条
[1]   Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada [J].
Abed, Y ;
Hardy, I ;
Li, Y ;
Boivin, G .
JOURNAL OF MEDICAL VIROLOGY, 2002, 67 (04) :589-595
[2]   Influenza neuraminidase [J].
Air, Gillian M. .
INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2012, 6 (04) :245-256
[3]  
[Anonymous], REC COMP INFL VIR VA
[4]  
[Anonymous], 2015, ANTIVIRAL RESISTANCE
[5]  
[Anonymous], 2015, WHO CONS INF M COMP
[6]  
[Anonymous], AG AGD H HIST PAND
[7]   Baculoviral Co-Expression of HA, NA and M1 Proteins of Highly Pathogenic H5N1 Influenza Virus in Insect Cells [J].
Behzadian, Farida ;
Goodarzi, Zahra ;
Fotouhi, Fatemeh ;
Saberfar, Esmaeil .
JUNDISHAPUR JOURNAL OF MICROBIOLOGY, 2013, 6 (09)
[8]   Recombinant Soluble, Multimeric HA and NA Exhibit Distinctive Types of Protection against Pandemic Swine-Origin 2009 A(H1N1) Influenza Virus Infection in Ferrets [J].
Bosch, Berend Jan ;
Bodewes, Rogier ;
de Vries, Robert P. ;
Kreijtz, Joost H. C. M. ;
Bartelink, Willem ;
van Amerongen, Geert ;
Rimmelzwaan, Guus F. ;
de Haan, Cornelis A. M. ;
Osterhaus, Albert D. M. E. ;
Rottier, Peter J. M. .
JOURNAL OF VIROLOGY, 2010, 84 (19) :10366-10374
[9]   Immunization against influenza A virus: Comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system [J].
Brett, IC ;
Johansson, BE .
VIROLOGY, 2005, 339 (02) :273-280
[10]   Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin [J].
Bright, Rick A. ;
Carter, Donald M. ;
Daniluk, Shannon ;
Toapanta, Franklin R. ;
Ahmad, Attiya ;
Gavrilov, Victor ;
Massare, Mike ;
Pushko, Peter ;
Mytle, Nutan ;
Rowe, Thomas ;
Smith, Gale ;
Ross, Ted M. .
VACCINE, 2007, 25 (19) :3871-3878